BioDir 研究关注：Bio Korea 2026 kicks off with spotlight on oligonucleotides
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the prese...
## 事件概览
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the prese...
## 核心信息
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.
## 为什么值得关注
这条内容与 drug discovery 相关，可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 43 分的候选评分。
## 发布提示
发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv，应明确标注其为预印本，尚未经过同行评议。